Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Pharmesis International (SGX:BFK) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Pharmesis International 9-Day RSI Related Terms
SGX:BFK vs ZTS, UTHR, VTRS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pharmesis International's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmesis International 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pharmesis International's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Pharmesis International's 9-Day RSI falls into.
Pharmesis International (SGX:BFK) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmesis International (SGX:BFK) has a 9-Day RSI of 47.84 as of Sep. 04, 2026. According to the industry distribution chart, Pharmesis International ranks #545 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 52.1%.
Is Pharmesis International's 9-Day RSI too high?
Pharmesis International's current 9-Day RSI is 47.84. The Drug Manufacturers industry median 9-Day RSI is 46.99. Pharmesis International's value of 47.84 is 1.8% above this industry median. Based on the distribution chart, Pharmesis International ranks #545 out of 1046 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Pharmesis International has a GF Score™ of 34/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmesis International's 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Pharmesis International ranks #545 out of 1046 companies for 9-Day RSI. This places Pharmesis International in the lower half of its industry. The industry median 9-Day RSI is 46.99. Pharmesis International's value of 47.84 is 1.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 46.99, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmesis International's current 9-Day RSI of 47.84 is 1.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 46.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmesis International's current 9-Day RSI is 47.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmesis International stock overvalued right now?
Based on GuruFocus' analysis, Pharmesis International (SGX:BFK) is currently considered Modestly Undervalued. The stock's GF Value™ is S$0.16, compared to a current price of S$0.13 — trading 21.9% below its estimated fair value. The current 9-Day RSI is 47.84 and 1.8% above the Drug Manufacturers industry median of 46.99. Pharmesis International's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Pharmesis International (SGX:BFK), the current 9-Day RSI is 47.84 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmesis International (SGX:BFK) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmesis International stock appears to be undervalued.
The current stock price of S$0.13 is trading 21.9% below its estimated GF Value™ of S$0.16.
GuruFocus considers Pharmesis International to be Modestly Undervalued.
Key valuation signals for SGX:BFK:
9-Day RSI: 47.84
GF Value™: S$0.16 vs. price of S$0.13 (21.9% below fair value)
Industry Position: 1.8% above the Drug Manufacturers median (#545 of 1046)
No single metric tells the full story. See the SGX:BFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmesis International Ltd is an investment holding company. The company manufactures pharmaceutical products in the form of tablets, granules, pills, and other forms. Its operating segments are Western drugs/TCH Procurement, which are chemically formulated drugs and are marketed under the Kinna brand; TCM-formulated drugs/IP rental, which refer to Traditional Chinese Medicine and are marketed under the Longlife brand; and Distribution, which derives maximum revenue, refers to agency products and internally manufactured products which are marketed through the distribution arm. The company derives revenue from the sale of medicines to domestic customers in China.
34GF Score
Get the complete analysis for SGX:BFK
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:BFK has been successfully added to your 
